Co-operative membrane disruption between cell-penetrating peptide and cargo: Implications for the therapeutic use of the Bcl-2 converter peptide D-NuBCP-9-r8

Molecular Therapy

Volumn 19, Issue 12, 2011, Pages 2124-2132

  Watkins, Catherine L ^a   Sayers, Edward J ^a,b   Allender, Chris ^a   Barrow, David ^b   Fegan, Christopher ^c   Brennan, Paul ^b   Jones, Arwyn T ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

^c UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; CELL PENETRATING PEPTIDE; CHIMERIC PROTEIN; D NUBCP 9 R8 PROTEIN; NUCLEAR RECEPTOR RELATED FACTOR 1; PHENYLALANINE; PROTEIN BCL 2; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; AMINO TERMINAL SEQUENCE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL DEATH; CELL VIABILITY; CELLULAR DISTRIBUTION; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; GENE MUTATION; HUMAN; HUMAN CELL; MEMBRANE DAMAGE; PROTEIN EXPRESSION; PROTEIN TARGETING;

EID: 82955236227     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2011.175     Document Type: Article

References (27)

1. Borden, EC, Kluger, H and Crowley, J (2008). Apoptosis: a clinical perspective. Nat Rev Drug Discov 7:959.
2. Ashkenazi, A (2008). Directing cancer cells to self-destruct with pro-apoptotic receptor agonists. Nat Rev Drug Discov 7:1001-1012.
3. Cotter, TG (2009). Apoptosis and cancer: the genesis of a research field. Nat Rev Cancer 9:501-507.
4. Reed, JC (2008). Bcl-2-family proteins and hematologic malignancies: history and future prospects. Blood 111:3322-3330.
5. Yip, KW and Reed, JC (2008). Bcl-2 family proteins and cancer. Oncogene 27:6398-6406.
6. Szakacs, G, Paterson, JK, Ludwig, JA, Booth-Genthe, C and Gottesman, MM (2006). Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5:219-234. (Pubitemid 43336035)
7. Jones, AT (2008). Gateways and tools for drug delivery: endocytic pathways and the cellular dynamics of cell penetrating peptides. Int J Pharm 354:34-38.
8. Foged, C and Nielsen, HM (2008). Cell-penetrating peptides for drug delivery across membrane barriers. Expert Opin Drug Deliv 5:105-117. (Pubitemid 351234112)
9. Henriques, ST, Melo, MN and Castanho, MA (2006). Cell-penetrating peptides and antimicrobial peptides: how different are they? Biochem J 399:1-7. (Pubitemid 44505401)
10. Foerg, C and Merkle, HP (2008). On the biomedical promise of cell penetrating peptides: limits versus prospects. J Pharm Sci 97:144-162.
11. Fonseca, SB, Pereira, MP and Kelley, SO (2009). Recent advances in the use of cellpenetrating peptides for medical and biological applications. Adv Drug Deliv Rev 61:953-964.
12. Kolluri, SK, Zhu, X, Zhou, X, Lin, B, Chen, Y, Sun, K et al. (2008). A short Nur77-derived peptide converts Bcl-2 from a protector to a killer. Cancer Cell 14:285-298.
13. Tunnemann, G, Martin, RM, Haupt, S, Patsch, C, Edenhofer, F and Cardoso, MC (2006). Cargo-dependent mode of uptake and bioavailability of TAT-containing proteins and peptides in living cells. FASEB J 20:1775-1784. (Pubitemid 44933791)
14. Kosuge, M, Takeuchi, T, Nakase, I, Jones, AT and Futaki, S (2008). Cellular internalization and distribution of arginine-rich peptides as a function of extracellular peptide concentration, serum, and plasma membrane associated proteoglycans. Bioconjug Chem 19:656-664. (Pubitemid 351431397)
15. Watkins, CL, Schmaljohann, D, Futaki, S and Jones, AT (2009). Low concentration thresholds of plasma membranes for rapid energy-independent translocation of a cellpenetrating peptide. Biochem J 420:179-189.
16. Watkins, CL, Brennan, P, Fegan, C, Takayama, K, Nakase, I, Futaki, S et al. (2009). Cellular uptake, distribution and cytotoxicity of the hydrophobic cell penetrating peptide sequence PFVYLI linked to the proapoptotic domain peptide PAD. J Control Release 140:237-244.
17. Heitz, F, Morris, MC and Divita, G (2009). Twenty years of cell-penetrating peptides: from molecular mechanisms to therapeutics. Br J Pharmacol 157:195-206.
18. Stewart, KM, Horton, KL and Kelley, SO (2008). Cell-penetrating peptides as delivery vehicles for biology and medicine. Org Biomol Chem 6:2242-2255. (Pubitemid 351863664)
19. Duchardt, F, Fotin-Mleczek, M, Schwarz, H, Fischer, R and Brock, R (2007). A comprehensive model for the cellular uptake of cationic cell-penetrating peptides. Traffic 8:848-866. (Pubitemid 46971632)
20. + leukaemia cells. Biochem J 403:335-342. (Pubitemid 46596590)
21. Moulton, HM, Nelson, MH, Hatlevig, SA, Reddy, MT and Iversen, PL (2004). Cellular uptake of antisense morpholino oligomers conjugated to arginine-rich peptides. Bioconjug Chem 15:290-299. (Pubitemid 38365188)
22. Abes, S, Moulton, HM, Clair, P, Prevot, P, Youngblood, DS, Wu, RP et al. (2006). Vectorization of morpholino oligomers by the (R-Ahx-R) 4 peptide allows efficient splicing correction in the absence of endosomolytic agents. J Control Release 116:304-313. (Pubitemid 44827406)
23. Takayama, K, Nakase, I, Michiue, H, Takeuchi, T, Tomizawa, K, Matsui, H et al. (2009). Enhanced intracellular delivery using arginine-rich peptides by the addition of penetration accelerating sequences (Pas). J Control Release 138:128-133.
24. Mason, AJ, Moussaoui, W, Abdelrahman, T, Boukhari, A, Bertani, P, Marquette, A et al. (2009). Structural determinants of antimicrobial and antiplasmodial activity and selectivity in histidine-rich amphipathic cationic peptides. J Biol Chem 284:119-133.
25. Shental-Bechor, D, Haliloglu, T and Ben-Tal, N (2007). Interactions of cationichydrophobic peptides with lipid bilayers: a Monte Carlo simulation method. Biophys J 93:1858-1871. (Pubitemid 47437571)
26. + and CD38-sub-clones derived from the same chronic lymphocytic leukemia patient have distinct gene expression signatures despite their monoclonal origin. Leukemia 21:687-696. (Pubitemid 46444552)
27. Shin, DS, Lee, JH, Suh, J and Kim, TH (2006). Elimination of surface debris generated by KrF excimer laser ablation of polyimide. Materials Science and Engineering a-Structural Materials Properties Microstructure and Processing 416:205-210. (Pubitemid 43103171)